Will Change in the Pharmaceutical Industry also Change the Industry's Pecking Order?

Bernard Munos is a Senior Fellow at FasterCures, a center of the Milken Institute, and the founder of the InnoThink Center for Research in Biomedical Innovation, a consultancy that helps biomedical research organizations become better innovators. Before that, he served as an advisor for corporate strategy at Eli Lilly, where he focused on disruptive innovation and the radical redesign of R&D. He is also a member of the Advisory Council of the National Center for Advancing Translational Sciences (NCATS), a non-executive Director of Glenmark Pharmaceuticals, a member of the Advisory Board of Science Translational Medicine, and an Advisor to or Board member of a dozen other companies or publicly-financed research organizations. His research has been profiled by Forbes magazine; he blogs about biomedical innovation on the Forbes website; and the popular industry newsletter FiercePharma named him one of the 25 most influential people in biopharma. He received his MBA from Stanford University, and holds other graduate degrees in animal science and agricultural economics from the Paris Institute of Technology for Life, Food and Environmental Sciences and the University of California, Davis.